Skip to main content
Roche signs triple-negative breast cancer biomarker deal with Phoenix

Roche Holding agreed to collaborate with Phoenix Molecular Designs to develop an assay that will detect activation of RPS6KA3 in patients with triple-negative breast cancer. Phoenix intends to use the diagnostic in a Phase I/Ib trial of its drug candidate PMD026 this year.

Full Story: